EFB Dengue Literature Review

Open Research Questions

19 min read

Open Research Questions

Research Question

What does the wiki’s ingested literature leave unanswered — and which of those gaps are specific enough that a nameable experiment or a nameable paper would close them?

Sources Used

This page aggregates the ## Questions Raised sections of every ingested source page, plus questions surfaced during council reviews and deep lints. It draws on:

Dengue primaries — Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue · Singh2026 - DENV-Specific Memory B Cell Subsets · Wrammert2012 - Plasmablast Responses in Acute Dengue · GarciaBates2013 - Plasmablast Response and Dengue Severity · GodoyLozano2016 - Lower IgG SHM Rates in Acute Dengue · Priyamvada2016 - Cross-Reactive Memory Plasmablasts in Secondary Dengue · Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool · Parameswaran2013 - Convergent Antibody Signatures in Dengue · Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue · Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling

Comparative benchmarks — Jenks2018 - DN2 B Cells and EF Pathway in SLE · Wei2007 - DN Memory B Cells in SLE · Tipton2015 - ASC Diversity and Origin in SLE · Scharer2019 - Epigenetic Programming in SLE B Cells · Anolik2004 - Rituximab and B Cell Abnormalities in SLE · Woodruff2020 - EF B Cell Responses in COVID-19 · Kaneko2020 - GC Loss and TFH Block in COVID-19 · Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection · William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice · Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells · Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation · Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation

Reviews and syntheses — Sanz2025 - Human Atypical B Cells Overview · Cancro2020 - Age-Associated B Cells · Glaros2025 - Multilayered Identity of B Cell Memory · Lamprinou2026 - ABCs and DN B Cells · Beckers2023 - Origins and Functions of DN B Cells · Bhattacharya2016 - Memory B Cell Subset Selection in Secondary Dengue

Synthesis

What this page is, and what it replaced. These questions accumulated for four months as Watch Items in state.md, on the reasoning that an open question should be tracked. That was a category error: a watch item is something a wiki session can close, and none of these can be — they close when an experiment is run or a paper is ingested, not when the wiki is edited. Seventy-nine of them had built up in cold storage where nothing read them. Gathered here and grouped, the redundancy becomes the signal: the same few questions are being asked independently by papers that never cite each other.

A. Identity — is the dengue “DN” compartment actually DN2?

The wiki’s central cell is defined differently by every paper that measures it, and no dengue study has the markers to arbitrate.

  • The two dengue DN measurements are not measuring the same cell. Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue gates IgD⁻CD27⁻ then CD21⁻CD11c⁺; Singh2026 - DENV-Specific Memory B Cell Subsets gates CD27⁻CD21⁻ on DENV-specific cells; neither matches the CD11c-primary definition of Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection. Their findings cannot simply be pooled.
  • No dengue study has stained T-bet, CXCR5, FCRL5 or ZEB2 within the DN gate. Formal DN2 confirmation needs intracellular T-bet plus surface CXCR5 on IgD⁻CD27⁻ cells from acute samples.
  • How badly have dengue studies undercounted? CITE-seq shows CD21⁻CD27⁻ captures only ~45% of transcriptomically-defined alternative-lineage cells, with CD11c the better discriminator (Sutton2021). Every dengue study using the CD21-based gate — Ansari2025, Singh2026, GarciaBates2013 — is therefore a lower bound of unknown size.
  • Does the CD21⁻/CXCR5⁻ concordance hold in dengue? Jenks2018 - DN2 B Cells and EF Pathway in SLE reports <5–10% discordance in SLE. Whether that transfers determines whether “DN2-phenotype” approximates true DN2.
  • Could CD27 shedding be manufacturing the DN population? ADAM17-mediated CD27 cleavage under high TNF/IL-6 — both features of dengue — would inflate apparent DN frequencies. Measuring soluble CD27 in matched serum would bound the artefact. No dengue study addresses it.
  • Do DN2 cells expand in acute dengue at all, and on what kinetics relative to the plasmablast wave? The panel requirement (CXCR5 within IgD⁻CD27⁻) means this has probably never been measured.
  • Is the DN1:DN2 ratio informative of severity or of EF-vs-GC dominance? The Sanz lab has now reported this ratio as an outcome in three settings (SLE, acute COVID-19, cutaneous lupus); no dengue equivalent exists.
  • Does DN3 expand in dengue alongside DN2? DN3 (CD21⁻CD11c⁻ on the Emory axis) are pre-plasmablasts expanded in COVID-19 and SLE.
  • Does DN4 exist in dengue, and does the standard EF gate discard it? Lamprinou2026 - ABCs and DN B Cells adds a CXCR5⁺CD11c⁻ DN4 subset; CXCR5⁻-focused gating systematically discards the CXCR5⁺ DN subsets (DN1, DN4).
  • Is the IgD⁻CD27⁻ ABC fraction transcriptomically identical to DN2? ABC ≠ DN2 across the whole ABC superset (Maul 2021 via Lamprinou2026); whether the distinction persists within the DN gate is untested and needs paired transcriptomics of sorted populations.
  • Which DN subset are the DENV-specific CD27⁻CD21⁻ cells that accumulate in secondary dengue? DN2 effectors or DN1 memory? The Singh2026 panel lacks CXCR5 and CD11c and cannot say.
  • Can the T-bet/ZEB2 signature retrospectively identify EF-derived B cells in existing dengue scRNA-seq datasets? A low-cost computational test of whether DN2-like cells exist in dengue at all.
  • Is ZEB2 elevated in acute dengue B cells? ZEB2 represses Mef2b, giving a mechanistic basis for EF/GC antagonism. Testable by re-analysis.

B. Origin — extrafollicular versus germinal centre

The wiki’s spine claim is GC-independence. The direct evidence is murine, acute, and viral; everything else is inference.

  • Does GC-independent generation hold outside acute viral infection? The fate-mapping result (Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells) covers one murine acute viral model. The chronic settings that supply most of this wiki’s benchmarks — malaria, HIV, SLE — are untested, and there is no human equivalent of GC fate mapping. Consequence for wiki prose: EF generation is strongly supported in acute murine viral infection and inferred everywhere else.
  • Two entry routes into EF effector output, and nobody knows which operates in dengue. Glaros2025 - Multilayered Identity of B Cell Memory reports higher BCR affinity plus stronger T help favouring the early-PC limb; Jenks2018 reports DN2→PC on TLR7 + IL-21 + IFN-γ without BCR stimulation, with CD40L inhibiting DN2 generation. The affinity route predicts DENV-specific, affinity-selected plasmablasts; the innate route predicts a broader, less selected output — which is the one consistent with the ADE story.
  • Are dengue plasmablasts naive-derived or memory-derived? In SLE flares naive cells dominate ASC precursors, not memory recall. Anamnestic kinetics in dengue (day 4–7 peak, secondary ≫ primary) favour memory, but naive contraction in secondary disease is also consistent with recruitment. Needs clonal tracking or connectivity NGS.
  • Intermediate SHM does not resolve the question. Convergent-CDR3-bearing dengue cells carry 4.4–6.9% V mutation, sitting between the EF (<3%) and GC (~7.3%) benchmarks from SLE. Three models survive: GC-matured memory recalled via EF; a mixture of both populations; or more extensive EF maturation in dengue than in SLE.
  • Why is SHM lower in secondary than primary dengue? Competing models: a stronger innate-like EF response in secondary infection, versus original antigenic sin rapidly activating low-SHM cross-reactive memory that outcompetes high-SHM serotype-specific clones.
  • Are the high-SHM plasmablasts of secondary dengue GC-experienced? Mean 18.1 VH mutations is consistent with GC memory recall but does not exclude EF-matured memory accumulating comparable SHM over repeated exposures.
  • Does the murine EF SHM rate translate to humans? ~0.3 mutations/Vκ/generation (William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice) is the only quantitative per-generation estimate; human data compare total mutation load between populations, not rates. Bears directly on how much SHM an EF response could plausibly accumulate inside an acute illness.
  • Are IgM⁺ memory B cells — the only subset significantly elevated in acute secondary dengue — EF- or GC-derived? BCR sequencing of sorted IgM⁺ DENV-specific cells would settle it.
  • Is there concurrent GC activity in dengue? Pre-GC (Bm2ʹ, IgD⁺CD38^hi) cells are a distinct rituximab-resistant SLE population (Anolik2004 - Rituximab and B Cell Abnormalities in SLE); no dengue paper has tracked that gate. Relatedly, detecting Bcl-6⁺ TFH in dengue-draining lymph nodes would distinguish dengue from COVID-19, where GC-TFH are completely absent (Kaneko2020 - GC Loss and TFH Block in COVID-19).
  • Does acute dengue produce a transient GC tolerance failure? Autoreactive VH4.34 memory is expanded in SLE and normalises after rituximab. Needs paired acute/convalescent repertoire data.
  • Do activated naive cells expand in acute dengue? Tipton2015 - ASC Diversity and Origin in SLE defines them as major EF ASC precursors in SLE; CD19^hi CD21⁻ CD24⁻ within IgD⁺CD27⁻ is assessable in existing dengue data.
  • Does the alternative-lineage framework apply to acute dengue? Dengue’s plasmablast expansion is more explosive than malaria’s — does that shift the balance from alternative memory toward PC differentiation, as Sutton’s Discussion proposes for SLE?
  • Primary-versus-secondary is a cross-disease gap, not just a dengue one. COVID-19 benchmarks a primary EF response: naive-derived and germline-dominant. Secondary dengue is memory-dominated and high-SHM. Whether primary dengue looks like the COVID-19 pattern is untested — and the wiki should say so wherever it uses COVID-19 as an analogue.

C. Drivers — TLR7, IL-21, IFN-γ and T help

  • ★ Nobody has measured TLR7 responsiveness in human B cells during dengue. DENV engages human TLR7 (Wang2006 - Flavivirus Activation of pDCs and TLR7 Signaling) and the SLE literature makes TLR7 the DN2 driver, but the joining experiment — R848 or DENV ssRNA on dengue-patient B cells — has not been done. The proposed TLR7 → AID → class switching without GC SHM (GodoyLozano2016 - Lower IgG SHM Rates in Acute Dengue) is entirely inferred.
  • The TLR7 timing paradox. TLR7 drives DN2 generation in the SLE literature, yet sustained TLR7/9 ligation suppresses ASC formation in mouse (Stone2019 - T-bet Promotes ASC Differentiation by Limiting IFN-gamma Inflammation). If both hold, TLR7 signalling must be timed — driving generation early, then withdrawn or overridden for those cells to secrete. Acute dengue supplies TLR7 ligand throughout.
  • Does the TLR9 co-stimulation model transfer? William2002 proposes chromatin-immune-complex TLR9 signalling as the driver of sustained EF activation and SHM; the direct analogue is TLR7 sensing of DENV ssRNA during viraemia.
  • Is Tfh-driven plasmablast generation also IL-21-dependent? The IL-21R-Fc blocking in Ansari2025 was performed only on CXCR5⁻PD-1⁺ cells; the parallel Tfh arm was never run.
  • Would blocking IL-21 spare neutralising titres? Anti-IL-21 cuts plasmablast output by ~60%. Whether that preferentially removes severity-associated non-neutralising IgG is the translational question.
  • Bulk serum cytokine assays may be looking in the wrong compartment. GarciaBates2013 found no correlation between serum IL-21 and plasmablast frequency; Ansari2025, twelve years later, identified Tph-derived paracrine IL-21 as the driver. FluoroSpot or intracellular staining is needed where serum assays returned null.
  • Are EF and GC pathways running simultaneously in dengue? CXCL13 is elevated alongside Tph dominance. Is the EF:GC ratio itself a severity biomarker?
  • Does the Tph → IL-21 → memory B cell → plasmablast axis produce ADE-competent IgG? The key translational question of the dengue EF model; needs paired Tph frequency and ADE assay data.
  • What does the GZMB⁺HOPX⁺ cytotoxic Tph subcluster do? No assigned function, and only 13 TCR clonotypes shared with helper Tph.
  • Does dengue TNF-α block GC TFH differentiation? TNF-α accumulation blocks Bcl-6⁺ TFH differentiation in COVID-19. If the same operates in dengue, it would mechanistically explain the low-SHM IgG findings — no GCs, therefore no GC-level SHM. Anti-TNF has been proposed as a GC rescue, though in a flavivirus it risks enhancing viraemia.
  • Does dengue show the AID⁺/Bcl-6⁻ dissociation? Preserved AID⁺ B cells alongside lost Bcl-6⁺ GC B cells is the strongest tissue evidence that AID operates extrafollicularly. Intracellular AID staining on acute dengue B cells would test it.
  • Does acute dengue produce AP-1/EGR chromatin remodelling? Scharer2019 - Epigenetic Programming in SLE B Cells identifies AP-1/EGR motif amplification as the SLE-specific layer on DN2 chromatin, distinct from the shared T-BET programme. Does an ssRNA virus with TLR7 activation and IFN-γ produce a transient version, and does it resolve after defervescence?
  • Is ATF3 a practical flow readout of EF activation? Induced by both TLR stimulation and cellular stress, and validated for intracellular flow in Scharer2019.
  • Does chronic dengue exposure epigenetically prime naive B cells in endemic settings? SLE resting naive cells carry 6,664 differentially methylated loci and NR4A1/NR4A3 upregulation. An analogous priming would lower the EF activation threshold in repeatedly-exposed populations.

D. Antibody output — cross-reactivity, ADE, autoreactivity and original antigenic sin

The largest cluster, and the one that carries the wiki’s translational weight.

  • ★ The wiki’s central functional claim has never been tested. “DN/atypical cells are the source of the low-fidelity, cross-reactive, autoreactive antibody” — no functional antibody output has ever been measured from sorted DN/atypical cells in any infection. Sutton2021 states this as its own limitation (no neutralisation, no ADE assays). The supporting autoantibody data is SLE-only and in vitro. Everything infection-side is inference from co-occurrence: plasmablast-derived mAbs are ADE-competent, and DN cells are expanded, with no experiment joining them.
  • Is the DN2 gate enriched for prior-serotype specificity? Cancro2020 - Age-Associated B Cells proposes the ABC pool as the substrate of antigenic imprinting in sequential viral infections; dengue is the paradigm case, and the wiki holds both halves separately — original antigenic sin at antibody level, DN expansion at cell level, with nothing joining them. Serotype-resolved antigen probes on a DN-gated population would test it directly.
  • Is OAS universal in secondary dengue? Preferential DENV1 neutralisation during DENV2 infection appeared in only 2 of 4 patients. Serotype-combination-dependent, interval-dependent, or individual clonal history?
  • Are the OAS antibodies specifically the ADE mediators? DENV1-biased mAbs that bind DENV2 weakly and fail to neutralise it are exactly the ADE profile. Needs ADE assays stratified by OAS versus non-OAS mAbs — and dose-response curves, since the 45/53-mAbs-enhance result came from a single concentration.
  • Does an EF-driven neutralising-antibody paradox exist in dengue? In COVID-19, high neutralising titres from EF-derived ASCs correlate with poor outcomes. Testable with paired B cell phenotyping plus serum neutralisation and ADE assays.
  • What do the convergent CDR3s bind? Public clonotypes shared across individuals and serotypes (Parameswaran2013; GodoyLozano2016) have unknown antigen targets and unknown neutralising-versus-enhancing character. Recombinant expression would settle both — and the convergent clones have never been cell-type resolved, having come from unsorted PBMC gDNA.
  • Is the VH4-34/VH1-69 enrichment in dengue plasmablasts transient EF autoreactivity or persistent? Both are autoantigen-associated V genes. Paired acute/convalescent repertoire data would distinguish the self-limited pattern seen after COVID-19 from something durable.
  • Does EF tolerance escape explain it? William2002 proposes that EF mutation escapes GC tolerance checkpoints because FDCs and Fas-mediated apoptosis are absent at extrafollicular sites — a mechanism that would directly predict the observed autoreactive V-gene enrichment.
  • Is the IGHV1-2 low-SHM association with severity causal? And do IGHV1-2- and IGHV1-69-using antibodies preferentially mediate ADE?
  • Is the Fc glycosylation of dengue plasmablast IgG pro-inflammatory? Afucosylated IgG enhances FcγRIIIa binding and ADCC; the massive dengue plasmablast wave produces predominantly non-neutralising IgG. No glycoproteomic data exists.
  • Is IgG3 enrichment a complement-mediated route to vascular leak? DN2-derived plasmablasts are IgG3-enriched in SLE, and alternative-lineage cells are IgG3-enriched in malaria-exposed donors. IgG3 is the most complement-activating subclass, and complement activation is a candidate mechanism in severe dengue.
  • What is the functional output of quiescent alternative memory on rechallenge? MBC1 cells have no functional data at all — recall could make them a source of cross-reactive or autoreactive antibody in secondary infection.
  • Are the germline-coded cross-reactive IgG antibodies even DENV-specific? Polyclonal CDRH3 diversity within biased IGHV segments suggests germline-encoded recognition, but no antigen-specific sorting was performed.
  • What activates the prM-specific and complex-epitope memory compartment? Plasmablasts are ~85% E-specific while memory B cells are primarily complex-epitope and prM-specific. If the Tph axis selectively activates E-specific memory, a separate pathway must drive the rest.
  • Are the IgM-only PB/MBC shared clones real? Rare CDR3s shared between plasmablasts and memory cells were exclusively IgM — either genuine cross-compartment lineage members, or low-affinity polyreactive artefacts of live-virus sorting.
  • Does the memory reprogramming of secondary dengue predict anything clinical? The shift toward IgG⁺/atypical/class-switched memory subsets — does it predict neutralising breadth, ADE-relevant cross-reactivity, or severity on subsequent infection?
  • Does chromatin-level “antigenic experience recording” explain the secondary-dengue triad? Cumulative antigenic stimulation progressively opens PC-associated loci including PRDM1, biasing memory toward PC differentiation over GC re-entry (Glaros2025 Fig. 4). Applied to dengue — a wiki synthesis, not a Glaros claim — this predicts the observed triad: a massive plasmablast burst, lower SHM in secondary than primary, and OAS-biased output, because a PC-biased recall bypasses the GC and therefore adds no new mutation. Testable by ATAC-seq at the PRDM1 locus on sorted DENV-specific memory B cells, primary versus secondary donors. See ATAC-seq and Original Antigenic Sin.
  • Is there a transient autoreactive EF response in dengue that resolves? Healthy COVID-19 subjects generate naive-derived autoreactive DN2 cells that resolve within months. Does secondary infection perpetuate these clones instead?
  • Interval or age? Brazilian adults with >20-year inter-infection intervals show infecting-serotype-dominant reactivity while Nicaraguan children with shorter intervals show previous-serotype dominance. Interval-dependent, age-dependent or serotype-specific is unresolved.

E. Kinetics, compartments, and what blood cannot see

  • ★ Circulating frequency is not pool size. Murine blood and splenic ABC pools are not in equilibrium, with an explicit caution against blood-only tracking, and human blood ABC frequencies fall on antiretroviral therapy — so circulating atypical cells may be an activated/mobilised state rather than a compartment readout. Every cellular measurement in this wiki’s dengue corpus is peripheral blood.
  • Is there a liver-resident atypical B cell compartment in dengue? Hepatic involvement is one of only two severe-dengue signs with a consensus operational definition, and Tissue-Resident Memory B Cell documents a precedent: GC-independent, hypermutated IgM⁺T-bet⁺ memory resident in liver in a GC-absent murine infection, plus atypical memory in chronic-HBV human liver. No dengue liver B cell data exist.
  • Are plasmablasts being undercounted because they never leave the tissue? If additional plasmablast subsets form in secondary dengue but are retained in secondary lymphoid organs, circulating analysis undercounts the response — and the retained subset might carry different specificities (prM or NS rather than E).
  • The CD27⁺ memory gate misses DN memory entirely. Gating memory as CD19⁺CD20⁺CD27⁺ excludes the whole IgD⁻CD27⁻ compartment, so “DENV-binding memory” in those studies is incomplete by construction.
  • Primary-versus-secondary plasmablast kinetics are underpowered everywhere. Only 4 of 46 subjects were primary infections in the foundational study; responses looked similar but the comparison was never powered. The distinction matters because primary responses should carry more IgM and different kinetics if naive-derived.
  • What explains the delayed memory peaks and the 12–18-month uptick in secondary dengue? Prolonged GC reactions, tissue redistribution, or subclinical re-exposure in an endemic setting — needs longitudinal sampling with GC markers or serology to exclude re-exposure.
  • What are the naive-like IgD⁺/IgM⁺ DENV-specific cells that persist to 18 months? True antigen-experienced cells with SHM, germline-encoded polyreactive B cells, or activated naive precursors. BCR sequencing would resolve it.
  • Is the massive B cell apoptosis in secondary dengue homeostatic or pathological? 60% caspase-3⁺ B cells in secondary disease, with Ki-67/caspase-3 and CD95/caspase-3 correlations. And given that DN2 cells uniquely lack apoptosis-pathway enrichment among SLE B cell subsets — are DN2-phenotype cells selectively spared?

F. Transfer from the comparative benchmarks

Most of this wiki is not about dengue. These questions ask what the benchmark literature is entitled to say about it.

  • ★ The infectious-disease case runs on transfer from autoimmunity — and should say so. The biomarker evidence is far stronger in SLE (SLEDAI correlation; DN versus VH4.34 IgG R²=0.8; nephritis p=0.025; rituximab resolution; belimumab response tracking) than in infection. The transfer is licensed by a conserved cross-disease transcriptional programme — but that programme is review-carried, transcriptomic, drawn from chronic settings, dengue-untested, and internally contested. Grant and thesis text should make the transfer explicit and defend it rather than assume it.
  • Does dengue patient heterogeneity follow an EF-dominant versus GC-dominant endotype pattern? SLE patients segregate into endotypes predicting severity and vaccine-response quality. Directly relevant methodologically: in cutaneous lupus, structure was recovered only by unsupervised clustering on subset frequencies, not by group means — if a comparable bimodality exists in dengue, a severity-group mean comparison dilutes the signal toward null.
  • Ansari2025’s cohort is predominantly secondary infection, which changes what its DN cells are. Sanz2025 insists CD11c⁺T-bet⁺CD21lo identity is context-dependent (primary versus recall), predicting that these CD21⁻CD11c⁺ cells may be memory-derived DN2-like rather than the canonical naive-derived DN2 of SLE primary flares. This weakens the direct SLE analogy.
  • Is severe dengue the context that pushes atypical cells toward plasma-cell fate? Sutton reconciles the pre-plasmablast model (SLE) with the memory model (healthy/infection) via context dependence, with chronic TLR7 stimulation driving PC fate. Severe secondary dengue overlaps SLE on inflammatory cytokines, TLR7 ligand and immune dysregulation.
  • Are dengue’s persistent DENV-specific CD27⁻CD21⁻ cells “memory DN2”? Antigen-specific DN2 and DN3 persist >1 year after SARS-CoV-2 mRNA vaccination, accounting for >50% of spike/RBD⁺ cells; Singh2026’s cells persist to 18 months. The MBC1 cluster gives transcriptomic support for a quiescent memory-DN2 population — whether dengue generates an equivalent is untested.
  • Species discordance in depletion sensitivity is unresolved. Murine ABCs resist anti-CD20/anti-BLyS depletion while human SLE ABCs are sensitive. Species difference or disease-stage difference determines whether B-cell-depletion findings transfer at all.
  • Could the SLE epigenetic biomarkers generalise? 111 CpGs discriminate SLE from healthy B cells across all subsets — a candidate readout of EF pathway activation in other EF-dominant diseases, severe dengue included.

Open Questions

Questions this page raises about itself:

  • Which of these are worth converting into ingest targets? Several would be closed, or sharply narrowed, by papers already named in the queue — the human atypical-memory primaries (Moir 2008, Weiss 2009), the cross-disease ABC transcriptomics (Holla 2021), and the two-signal primary (Naradikian 2016).
  • Which are dead? A question asked by a 2013 paper and never revisited by any of the ~20 papers ingested since may have been answered outside this wiki’s corpus. Nothing here has been checked against literature the wiki has not read, and under the standing PDF-only rule nothing will be without an explicit instruction.
  • Does the redundancy mean anything? The same origin question (EF versus GC) is asked independently by papers spanning 2002 to 2026 that largely do not cite each other. That is either a genuinely hard problem or a sign the field lacks a decisive assay — worth distinguishing.

DN2 B Cell · Atypical B Cell · Double-Negative B Cell · Plasmablast · Extrafollicular Response · Germinal Center · Somatic Hypermutation · Class Switch Recombination · Original Antigenic Sin · Antibody-Dependent Enhancement · TLR7 · IL-21 · T-bet · ZEB2

Analyses: Why DN B Cells Matter - Disease Relevance and Infectious Disease Case · Mechanistic Case for DN and DN2 Cells in Dengue · Thesis Objectives and Grant Pitch · Notable Findings · External Citation Audit

Graph View

Backlinks